| The Influence of Inflammatory Bowel Disease and Its Treatment with 5-Aminosalicylic Acid on Pregnancy and Fetal Outcome |
|
Ji Hun Choi, Hye Seung Yoo, Suk-Kyun Yang, Seung-Jae Myung, Yun Kyung Cho, Yun-Jung Lee, Jeong-Sik Byeon, Gin Hyug Lee, Hwoon-Yong Jung, Weon-Seon Hong, Jin-Ho Kim, Young Il Min |
|
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
|
| 염증성 장질환과 5-ASA 투여가 임신 및 태아에 미치는 영향 |
|
최지훈, 유혜승, 양석균, 명승재, 조윤경, 이윤정, 변정식, 이진혁, 정훈용, 홍원선, 김진호, 민영일 |
|
울산대학교 의과대학 서울아산병원 내과학교실 |
|
|
| Abstract |
Background/Aims
5-Aminosalicylic acid (5-ASA) preparations are the first-line drugs in the treatment of inflammatory bowel disease (IBD). The aim of this study was to examine the influence of IBD and its treatment with 5-ASA on pregnancy and fetal outcome. Methods: A total of 56 patients (ulcerative colitis 41, Crohn's disease 15) experienced 84 pregnancies among 634 female patients with IBD between June 1989 and August 2003. The outcomes of 42 pregnancies exposed to 5-ASA during pregnancy were compared with those of 42 non-exposed pregnancies. Results: Pregnancy outcomes were not different between the exposed and non-exposed pregnancies in terms of live birth (85.7% vs 80.9%), abortion (11.9% vs 19.0%), stillbirth (2.4% vs 0%), preterm delivery (11.1% vs 5.9%), low birth weight (11.1% vs 8.8%), congenital malformation (2.8% vs 2.9%), and aggravation of disease during pregnancy (21.4% vs 16.7%). These figures appear to be similar to those of general population. Conclusions: Neither ulcerative colitis nor Crohn's disease has any significant impact on pregnancy outcome, and 5-ASA does not increase the risk of congenital malformation. (Intestinal Research 2004;2:26-30) |
| Key Words:
Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Pregnancy, 5-Aminosalicylic acid |
|
PDF Links
Full text via DOI
Download Citation
